Gut health startup The Good Bug raised Rs 100 crore ($12 million) in a Series B funding round, led by Susquehanna Asia Venture Capital, the venture capital arm of Susquehanna International Group. Existing investor Fireside Ventures also invested in this round.

Earlier, the Mumbai firm had raised $4 million in a Series A extension in 2024, which was led by Sharrp Ventures, the family office of Harsh Mariwala of the Marico Group. With this new funding, The Good Bug's cumulative capital raised now amounts to approximately $20 million.

The money will be used to grow research and development in microbiome science, increase clinical trials, increase distribution channels, and build brand recognition among consumers and healthcare providers, according to a press release by The Good Bug.

Established in 2022 by Keshav Biyani and Prabhu Karthikeyan, The Good Bug focuses on creating probiotic and gut wellness products that are intended to enhance digestion, immunity, and metabolic well-being. The company recently released Metabolically Lean, an autosomal GLP-1-based product that is positioned as a natural, non-surgical solution to weight-loss drugs such as Ozempic and Mounjaro. The product promises to naturally elevate GLP-1, which suppresses hunger and boosts metabolism.

Keshav Biyani, The Good Bug's co-founder, said, "The key utilization of these funds will be to speed up innovation in microbiome science and bacterial research. We will continue investing in clinical trials, brand-building, and hiring the best people in research, science, and business.